乳腺癌筛查:美国预防服务工作组推荐声明
美国预防服务工作组基于系统综述与协作建模,评估不同乳腺X线摄影筛查策略及补充影像对晚期乳腺癌发生与进展、乳腺癌发病率及死亡的影响。工作组以中等确定性结论认为,40至74岁女性每两年一次筛查乳腺X线摄影具有中等净获益(B推荐);对75岁及以上女性筛查及致密乳腺补充超声或磁共振筛查的证据不足(I声明)。
要点
- USPSTF推荐40至74岁女性每两年一次筛查乳腺X线摄影(B推荐)。
- 75岁及以上女性筛查乳腺X线摄影的获益与危害平衡证据不足(I声明)。
- 致密乳腺且筛查乳腺X线摄影阴性者补充超声或磁共振筛查证据不足(I声明)。
核心结论
- USPSTF以中等确定性结论认为40至74岁女性每两年一次筛查乳腺X线摄影具有中等净获益。
- USPSTF认为75岁及以上女性筛查乳腺X线摄影的获益与危害平衡证据不足。
- USPSTF认为致密乳腺且筛查乳腺X线摄影阴性者补充超声或磁共振筛查的获益与危害平衡证据不足。
研究设计与样本
- USPSTF委托系统综述评价不同乳腺X线摄影筛查策略(开始与停止年龄、间隔、 modality、补充影像、个性化筛查)对晚期乳腺癌发生与进展、乳腺癌发病率及乳腺癌特异性或全因死亡的影响。
- USPSTF委托协作建模研究以补充系统综述证据。
- 目标人群为40岁及以上、乳腺癌平均风险的顺性别女性及所有其他出生时指定为女性者。
主要发现
- 2023年估计有43 170名美国女性死于乳腺癌。
- 非西班牙裔白人女性乳腺癌发病率最高,非西班牙裔黑人女性死亡率最高。
- USPSTF以中等确定性结论认为40至74岁女性每两年一次筛查乳腺X线摄影具有中等净获益。
- USPSTF认为75岁及以上女性筛查乳腺X线摄影的获益与危害平衡证据不足。
- USPSTF认为致密乳腺且筛查乳腺X线摄影阴性者补充超声或磁共振筛查的获益与危害平衡证据不足。
关键数值与推荐
- USPSTF推荐40至74岁女性每两年一次筛查乳腺X线摄影(B推荐)。
- USPSTF认为75岁及以上女性筛查乳腺X线摄影的获益与危害平衡证据不足(I声明)。
- USPSTF认为致密乳腺且筛查乳腺X线摄影阴性者补充超声或磁共振筛查的获益与危害平衡证据不足(I声明)。
临床怎么用
- 对40至74岁、乳腺癌平均风险的顺性别女性及所有其他出生时指定为女性者,USPSTF推荐每两年一次筛查乳腺X线摄影(B推荐)。
- 对75岁及以上女性,USPSTF认为筛查乳腺X线摄影的获益与危害平衡证据不足(I声明)。
- 对致密乳腺且筛查乳腺X线摄影阴性者,USPSTF认为补充超声或磁共振筛查的获益与危害平衡证据不足(I声明)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death. In 2023, an estimated 43 170 women died of breast cancer. Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate. OBJECTIVE: The USPSTF commissioned a systematic review to evaluate the comparative effectiveness of different mammography-based breast cancer screening strategies by age to start and stop screening, screening interval, modality, use of supplemental imaging, or personalization of screening for breast cancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and breast cancer-specific or all-cause mortality, and collaborative modeling studies to complement the evidence from the review. POPULATION: Cisgender women and all other persons assigned female at birth aged 40 years or older at average risk of breast cancer. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density. RECOMMENDATION: The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement).
引用
- Nicholson WK, Silverstein M, Wong JB, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024. PMID: 38687503. doi:10.1001/jama.2024.5534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。